ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRNA | MODERNA INC | Healthcare | $93.61B | 14.10% |
2HUM | HUMANA INC | Healthcare | $53.29B | 8.03% |
3NTRA | NATERA INC | Healthcare | $46.83B | 7.06% |
4RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 5.96% |
5RVMD | REVOLUTION MEDICINES INC | Healthcare | $38.14B | 5.75% |
6CNC | CENTENE CORP | Healthcare | $34.79B | 5.24% |
7ILMN | ILLUMINA INC | Healthcare | $31.68B | 4.77% |
8ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 4.37% |
9VTRS | VIATRIS INC | Healthcare | $23.70B | 3.57% |
10CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $16.33B | 2.46% |
11GKOS | GLAUKOS CORP | Healthcare | $14.56B | 2.19% |
12BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $14.22B | 2.14% |
13HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 1.73% |
14KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 1.64% |
15HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 1.48% |
16SYRE | SPYRE THERAPEUTICS INC | Healthcare | $9.77B | 1.47% |
17TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 1.47% |
18TXG | 10X GENOMICS INC | Healthcare | $7.77B | 1.17% |
19KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 1.14% |
20AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 1.14% |
21TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 1.08% |
22ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 1.07% |
23KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 1.03% |
24LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 1.00% |
25IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 0.97% |
26ERAS | ERASCA INC | Healthcare | $5.52B | 0.83% |
27CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $5.44B | 0.82% |
28LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $5.38B | 0.81% |
29HTFL | HEARTFLOW INC | Healthcare | $5.21B | 0.79% |
30DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 0.78% |
31DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.52B | 0.68% |
32ITGR | INTEGER HOLDINGS CORP | Healthcare | $4.30B | 0.65% |
33TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 0.63% |
34CDNA | CAREDX INC | Healthcare | $4.19B | 0.63% |
35RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 0.60% |
36PLSE | PULSE BIOSCIENCES INC | Healthcare | $3.84B | 0.58% |
37AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $3.84B | 0.58% |
38ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.57% |
39OGN | ORGANON & CO | Healthcare | $3.65B | 0.55% |
40ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.56B | 0.54% |
41IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 0.53% |
42ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.53% |
43AXGN | AXOGEN INC | Healthcare | $3.31B | 0.50% |
44XNCR | XENCOR INC | Healthcare | $2.86B | 0.43% |
45ATRC | ATRICURE INC | Healthcare | $2.85B | 0.43% |
46NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.37% |
47REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.31% |
48VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.31% |
49MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.30% |
50AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.28% |
51BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 0.27% |
52ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.27% |
53SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.24% |
54ABSI | ABSCI CORP | Healthcare | $1.57B | 0.24% |
55AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.22% |
56KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.21% |
57LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.21% |
58OMER | OMEROS CORP | Healthcare | $1.30B | 0.20% |
59CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.19% |
60INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 0.19% |
61DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.23B | 0.19% |
62VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.18% |
63NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.18% |
64BVS | BIOVENTUS INC | Healthcare | $915M | 0.14% |
65NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.10% |
66CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.10% |
67CLYM | CLIMB BIO INC | Healthcare | $639M | 0.10% |
68SRZN | SURROZEN INC | Healthcare | $604M | 0.09% |
69IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.09% |
70RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.08% |
71PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.06% |
72MASS | 908 DEVICES INC | Healthcare | $407M | 0.06% |
73TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.05% |
74FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.04% |
75QTTB | Q32 BIO INC | Healthcare | $264M | 0.04% |
76GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.03% |
77AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.03% |
78KRRO | KORRO BIO INC | Healthcare | $196M | 0.03% |
79ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.03% |
80BDSX | BIODESIX INC | Healthcare | $109M | 0.02% |
81CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.01% |
82ICCC | IMMUCELL CORP | Healthcare | $93M | 0.01% |
83RLYB | RALLYBIO CORP | Healthcare | $84M | 0.01% |
84NRXS | NEURAXIS INC | Healthcare | $82M | 0.01% |
85YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.01% |
86ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $663.72B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 93% toward Large, 77% toward Growth. +5% unclassified (7 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 12.2% | -13.0% |
| 3 yearsp.a. | 23.5% | -1.0% |
| 5 yearsp.a. | 8.8% | 1.8% |
| 10 yearsp.a. | 14.5% | 4.1% |
| Since inceptionp.a. | 13.7% | 2.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 18.4% | -6.1% |
| 2025 | 17.4% | 1.4% |
| 2024 | 32.9% | 30.2% |
| 2023 | -9.4% | -34.7% |
| 2022 | -9.9% | 31.4% |
| 2021 | 17.0% | 26.3% |
| 2020 | 38.7% | -9.8% |
| 2019 | 29.9% | -9.1% |
| 2018 | -13.3% | -0.4% |
| 2017 | 37.6% | 25.0% |
| 2016 | -20.6% | 18.9% |
| 2015 | -18.7% | -32.2% |
| 2014 | 21.8% | -14.1% |
| 2013 | 71.8% | 26.5% |
| 2012 | 23.1% | -8.9% |
| 2011 | 23.2% | 23.3% |
| 2010 | 10.8% | -8.7% |
| 2009 | 23.5% | -20.7% |
| 2008 | -20.6% | -0.5% |
| 2007 | 18.3% | 39.5% |
| 2006 | -9.8% | -22.3% |
| 2005 | 17.6% | 22.5% |
| 2004 | 26.6% | 15.3% |
| 2003 | 46.8% | -20.8% |
| 2002 | -22.9% | 17.4% |
| 2001 | 1.0% | 36.7% |
| 2000 | 21.7% | -44.6% |
| 1999 | 93.8% | 70.2% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare 12-Month Momentum Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 12-Month Momentum signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.